Abstract: Process for preparing a human thrombin concentrate from the PPSB fraction of plasma that does not involve any addition of factors of animal origin to induce activation of the prothrombin to produce thrombin, and which includes a viral inactivation step using solvent-detergent and purification by cation exchange chromatography. The choice of a protective medium ensures the high specific activity of the final product. The thrombin concentrate obtained using this process is intended for therapeutic use, either alone, to serve as a local hemostatic agent, or in combination with a fibrinogen concentrate to form biological glue.

Abstract: New strains of microorganisms producing anti-Campylobacter metabolites have been identified which have the ability to utilize mucin as a sole substrate for growth and the ability to reduce and/or inhibit the incidence of Campylobacter jejuni colonization in poultry.

Abstract: The present invention is directed to a stable pharmaceutical composition wherein the absorbability of a lipophilic drug which is insoluble or practically insoluble in water or another drug such as a bioactive peptide in oral administration has been improved to such extent that a high level of blood concentration can be retained, and to a method for producing such a stable pharmaceutical composition. The pharmaceutical composition of the present invention offers improvements in the absorbability, for example, a high level of blood concentration can be retained for a long time in oral administration because it is highly resistant to lipase. Also, the pharmaceutical composition is highly safe because the emulsifier used is derived from mammalian milk.

Abstract: A method for increasing production of inositol from a nutrient medium is disclosed. The wild strain of Saccharonyces cerrevisae was modified by deleting the OPI1 gene locus. The modified strain was fermented in various media, both artificial and natural, to increase the production of inositol from the medium. Using a balanced synthetic nutrient medium, a glucose feed rate of 100 g/l and adding ammonium sulfate as a nitrogen source gave an almost 10-fold increase in inositol production, compared to production under more typical conditions. Using almond hull juice as a feedstock, batch conditions showed no measureable increase in inositol production but continuous fermentation yielded almost a 50% increase in inositol concentration.

Abstract: The invention provides a method for the growth promotion of animals, comprising orally administering into animals killed microbial cells of bacteria belonging to the genus Clostridium, and also provides a powder composition, which comprises as essential ingredients killed microbial vegetative cells of bacteria belonging to the genus Clostridium, together with saccharides and/or starches.

Abstract: An economic protein can be produced by using silkworms. The silkworms are chilled, warmed, and then orally infected with a virus in which a gene coding the target protein has been inserted. The silkworms so infected are then raised, followed by the collection of the target protein from the silkworms.

Abstract: An isolated Pseudomonas cepacia strain having the identifying characteristics of Pseudomonas cepacia NCSU strain 5.5B (A.T.C.C. No. 55,344) is disclosed. Also disclosed are a biocontrol agent comprising the aforementioned strain and a method of controlling Rhizoctonia comprising the step of administering such a biocontrol agent in an amount sufficient to inhibit the growth of Rhizoctonia solani.

Abstract: Disclosed is a fibrinolysis and fibrinogenolysis treatment which includes parenterally introducing into the body of a human patient human plasmin in fibrinolytically and fibrinogenolytically active form at a concentration and for a time sufficient to permit fibrinolytically and fibrinogenolytically active human plasmin to reach a concentration about the site of an intravascular clot sufficient to lyse the clot and/or to reduce circulating fibrinogen levels.

Abstract: The present invention provides adducts of human t-PA derivatives, which comprise a t-PA derivative that lacks the Finger, Growth Factor and Kringle 1 domains, bound to an amphipathic molecule. The invention also provides methods for preparing the adducts and compositions for the treatment of thromboembolic disorders.

Abstract: A process for producing cultures of Gliocladium virens for use as biocontrol agents wherein the production of viridiol is inhibited. Cells of Gliocladium virens are grown in a culture medium and under conditions effective to produce gliotoxin and/or gliovirin, wherein the culture medium includes an amount of a fungicidal steroid inhibitor which is effective to inhibit production of viridiol but which does not substantially inhibit the growth of G. virens. Following recovery, the resultant culture may be used as a biocontrol agent for the control of plant diseases by application to the locus of a plant, seedling or seed to be protected. Coating seeds with the biocontrol agent prior to planting has been found to be particularly effective for the control of soilborne root or seedling diseases.

Abstract: The content of phosphorus-containing components and the iron content of an edible vegetable or animal oil, preferably an oil such as soybean oil which has been wet-refined to remove mucilage, are reduced by enzymatic decomposition by contacting the oil with an aqueous solution of phospholipases A.sub.1, A.sub.2, or B and then separating the aqueous phase from the treated oil.